Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Vincristine (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 30 Jan 2019 Planned End Date changed from 2 Jul 2022 to 22 Jun 2022.
    • 30 Jan 2019 Planned primary completion date changed from 2 Jul 2022 to 22 Jun 2022.
    • 30 Jan 2019 Planned initiation date (estimated date of first participant enrollement) changed from 31 Dec 2018 to 23 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top